Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021:34:101534.
doi: 10.1016/j.rmcr.2021.101534. Epub 2021 Oct 21.

Idiopathic thrombocytopenic purpura as a hematologic manifestation of COVID-19 infection: A case report

Azadeh Laali  1 , Zohreh Kermanshah  2 , Hossein Keyvani  3   4 , Vahid Kaveh  5 , Sajad Karampoor  3   4
Affiliations
Case Reports

Idiopathic thrombocytopenic purpura as a hematologic manifestation of COVID-19 infection: A case report

Azadeh Laali et al. Respir Med Case Rep. 2021.

Abstract

The hematologic system is one of the vulnerable parts of the human body in coronavirus disease-2019 (COVID-19) infection. Lymphopenia and disseminated intravascular coagulation (DIC) are among the most frequent consequences of COVID-19. Idiopathic thrombocytopenic purpura is one of the common causes of thrombocytopenia in adults. It is defined by thrombocytopenia when platelet counts <105/μl in the absence of anemia and leukopenia. Traditionally, infections, typically viral, have been known as the main culprits of low platelet counts before the involvement of ITP. According to the literature, C virus (HCV), HIV, varicella-zoster virus (VZV), and cytomegalovirus (CMV) are considered secondary causative agents for the development of ITP. In this study, we reported a case that was afflicted with concurrent severe thrombocytopenia diagnosed as ITP and COVID-19 infection.

Keywords: COVID-19; Coronavirus; Idiopathic thrombocytopenic purpura; Thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

References

    1. Karampoor S., Hesamizadeh K., Maleki F., Farahmand M., Zahednasab H., Mirzaei R., Banoun H., Zamani F., Hajibaba M., Tabibzadeh A. A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19) Int. Immunopharm. 2021:108137. - PMC - PubMed
    1. Karampoor S., Hesamizadeh K., Shams Z., Novin A.G., Farahmand M., Zahednasab H., Mirzaei R., Zamani F., Hajibaba M., Bouzari B. The role of lovastatin in the attenuation of COVID-19. Int. Immunopharm. 2021:108192. - PMC - PubMed
    1. Karampoor S., Afrashteh F., Laali A. Persistent hiccups after treatment of COVID-19 with dexamethasone: a case report. Respiratory Medicine Case Reports. 2021;34:101515. - PMC - PubMed
    1. Park S.E. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) Clinical and experimental pediatrics. 2020;63(4):119. - PMC - PubMed
    1. Mirzaei R., Attar A., Papizadeh S., Jeda A.S., Hosseini-Fard S.R., Jamasbi E., Kazemi S., Amerkani S., Talei G.R., Moradi P. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19) Arch. Virol. 2021:1–22. - PMC - PubMed

Publication types